Malaria is an infectious disease caused by parasites of several Plasmodium spp.
Sickle cell disease (SCD) is a genetic disorder that poses a serious health threat in tropical Africa, which the World Health Organization has declared a public health priority.
In this mini-review we discuss and summarize what we have learned about African ethnic differences in susceptibility to malaria from immuno-epidemiological studies.
We report the presence of SNPs in Plasmodium falciparum K13-propeller gene in two African countries, Angola and Mozambique, where malaria is a serious public health problem.
Lessons from the failed WHO Blue Nile Health Project in central Sudan, 1980-1990
In this study, non-inferiority of AZCQ to AL was not demonstrated.
In the latest Annual Report of PMI (April 2014), they cite the reduction in mortality rates of children under five as proof of the beneficial impact of the anti-malarial work of PMI. Figure 1 of the report cites the following figures for the 15 PMI focus countries which have the best data. However, as in the past, they have not done a comparison with other countries in Africa. The same is true in general of the reports from the Roll Back Malaria program. For some strange reason they don't want to measure changes in malaria prevalence.
Do any of you have experience with the Garki Project, to add to my comments below? I would especially appreciate comments from those of you who knew what the thinking inside WHO Geneva was, at the time.
What lessons can we learn from the failure of the WHO Garki Malaria Project in Kano, Nigeria, 1970-1980?
SUGGESTIONS ON HOW TO SLOW THE RESISTANCE TREADMILL
The mosquito, Anopheles coluzzii is a major vector of human malaria in Africa with widespread distribution throughout the continent.